OTC boost for China Pharma
This article was originally published in The Tan Sheet
Executive Summary
China Pharma Holdings' 2008 net income grows 39 percent to $17.8 million due to a 76.6 percent sales increase of OTC cold and flu product PuSen OK (naproxen and pseudophedrine), the only generic version of Bayer's Aleve-D in China. Located in Haikou, the capital of the Hainan province, China Pharma markets 18 products treating infectious diseases, flu/cold and cardiovascular disease and makes nutritional supplements and traditional Chinese medicine, according to a March 17 release. The company is developing generic drugs for off-patent blockbuster drugs but is shifting to an innovative biopharmaceutical enterprise through the products in its pipeline
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.